p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11489795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

  2000cited by this paper
• K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

  1999cited by this paper
• Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.

  1999cited by this paper
• Pathological prognostic factors in breast cancer.

  1999cited by this paper
• TP53 gene mutations in plasma DNA of cancer patients

  1999cited by this paper
• p53 mutations in BRCA1-associated familial breast cancer.

  1998cited by this paper
• Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors

  1998cited by this paper
• K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer.

  1997cited by this paper
• p53 mutations in BRCA1-associated familial breast cancer.

  1997cited by this paper
• Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.

  1996cited by this paper
• Microsatellite alterations in serum DNA of head and neck cancer patients

  1996cited by this paper
• Microsatellite alterations in plasma DNA of small cell lung cancer patients

  1996cited by this paper
• Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.

  1996cited by this paper
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

  1996cited by this paper
• Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus

  1995cited by this paper
• An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis.

  1994cited by this paper
• Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus.

  1993cited by this paper
• Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• Activation of ras oncogenes preceding the onset of neoplasia.

  1990cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Neoplastic characteristics of the DNA found in the plasma of cancer patients.

  1989cited by this paper
• Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

  1989cited by this paper
• Isolation and characterization of DNA from the plasma of cancer patients.

  1987cited by this paper
• Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.

  1986cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Characterization of circulating molecules and activities in plasma of patients after allogeneic and autologous intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans

  2022cites this paper
• Prominent Prognostic Factors in Aggressive Breast Cancer: A Review

  2021cites this paper
• p53 Gene Mutation in Blood of Zebu Cattle with Squamous Cell Carcinoma of the Horn.

  2020cites this paper
• P53 and the Carcinoma of the Breast: A Review

  2020cites this paper
• The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients

  2020cites this paper
• Prognostic value of circulating tumor DNA in breast cancers

  2018cites this paper
• The prognostic value of circulating cell-free DNA in breast cancer

  2018cites this paper
• Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies.

  2017cites this paper
• Breast Cancer Biomarkers in Circulation

  2017cites this paper
• Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers

  2016cites this paper
• Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules.

  2016cites this paper
• Estudio de la utilidad clínica de la cuantificación de arn y adn plasmáticos en pacientes con cáncer de laringe e hipofaringe

  2016cites this paper
• [Potential of Cell-free Circulating DNA in Diagnosis of Cancer].

  2015cites this paper
• Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.

  2014cites this paper
• Trans-Oral Brush Biopsies and Quantitative PCR for EBV DNA Detection and Screening of Nasopharyngeal Carcinoma

  2014cites this paper
• Detection and Application of Circulating-Free Cell DNA in Hepatopathy

  2013cites this paper
• Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer

  2013cites this paper
• An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma

  2013cites this paper
• Circulating nucleic acids as biomarkers in breast cancer

  2013cites this paper
• Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients.

  2012cites this paper
• Marqueurs moléculaires prédictifs de réponse aux thérapies ciblées dans les cancers digestifs

  2012cites this paper
• Clinical Investigation : Head-and-Neck Cancer Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients

  2012cites this paper
• Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer

  2012cites this paper
• " Estudo da sobrevivência das doentes com cancro da mama, atendidas nas Unidades de Oncologia do Centro Hospitalar Médio Ave, EPE ".

  2011cites this paper
• Quantification of Circulating Plasma DNA in Friedreich's Ataxia and Spinocerebellar Ataxia Types 2 and 12

  2011cites this paper
• Circulating nucleic acids as a potential source for cancer biomarkers.

  2010cites this paper
• Plasma cell‐free DNA in ovarian cancer

  2010cites this paper
• Circulating Nucleic Acids in Health and Disease

  2010cites this paper
• Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

  2010cites this paper
• Plasma Cell-Free DNA Levels in Children on Peritoneal Dialysis

  2009cites this paper
• Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls.

  2009cites this paper
• Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

  2008cites this paper
• Multigene Methylation in Serum of Sporadic Chinese Female Breast Cancer Patients as a Prognostic Biomarker

  2008cites this paper
• Modeling Cancer Progression via Pathway Dependencies

  2008cites this paper
• Modeling Cancer Progression on the Pathway Level

  2008cites this paper
• Quantification of Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer

  2008cites this paper
• Point-of-care systems for rapid DNA quantification in oncology.

  2008cites this paper
• Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesis

  2008cites this paper
• Prognostic Value of LISCH7 mRNA in Plasma and Tumor of Colon Cancer Patients

  2007cites this paper
• Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases

  2007cites this paper
• Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

  2007cites this paper
• The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer.

  2006cites this paper
• Comparisons between capillary zone electrophoresis and real-time PCR for quantification of circulating DNA levels in human sera.

  2006cites this paper
• Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma.

  2006cites this paper
• Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential

  2006cites this paper
• Detection of circulating carcinoma cells in peripheral blood collected from patients with ovarian cancer by using different molecular markers - a preliminary report

  2006cites this paper
• Protein Prenylation: An (Almost) Comprehensive Overview on Discovery History, Enzymology, and Significance in Physiology and Disease

  2006cites this paper
• Circulating Nucleic Acids in Plasma or Serum (CNAPS) as Prognostic and Predictive Markers in Patients with Solid Neoplasias

  2005cites this paper
• Tumour Markers: Rationale Use

  2005cites this paper
• Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.

  2005cites this paper
• Breast cancer biomarkers and molecular medicine: part II

  2004cites this paper
• TP53 Gene in Blood Plasma DNA of Tumor Patients

  2004cites this paper
• Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer

  2004cites this paper
• Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

  2004cites this paper
• Cellular diagnostics: A challenge for laboratory medicine

  2004cites this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cites this paper
• Identification of Risk Factors for Early Neoplasm

  2004cites this paper
• A new quantitative method for circulating DNA level in human serum by capillary zone electrophoresis with laser‐induced fluorescence detection

  2004cites this paper
• DNA methylation in serum of breast cancer patients: an independent prognostic marker.

  2003cites this paper
• Breast cancer biomarkers and molecular medicine

  2003cites this paper
• TP 53 and Breast Cancer

  2003cites this paper
• Prevalence and Spectrum of p53 Mutations in White Hispanic and Non-Hispanic Women with Breast Cancer

  2003cites this paper
• TP53 and breast cancer

  2003cites this paper
• TP53 in carcinogenesis and cancer prevention

  2003cites this paper
• Circulating tumor DNA and its clinical applications

  2003cites this paper
• STEPping into position: a new player in the NMDA receptor game.

  2002cites this paper
• Feasibility of Breast Conservation after Neoadjuvant Chemotherapy in 58 Patients with Locally Advanced Breast Cancer Using p53 and MDR1 Genes as Predictors of Response

  2002cites this paper
• Molecular markers in the diagnosis and staging of breast cancer.

  2002cites this paper
• The p53 pathway in breast cancer

  2002cites this paper
• Tumor-speci¢c DNA in plasma of breast cancer patients

  2002cites this paper
• Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curves.

  2002cites this paper
• Circulating DNA: a new diagnostic gold mine?

  2002cites this paper
• Real-time PCR technology for cancer diagnostics.

  2002cites this paper
• The prognostic molecular markers in hepatocellular carcinoma.

  2002cites this paper
• Tumor-specific DNA in plasma of breast cancer patients

  2002cites this paper
• Circulating nucleic acids as a tumor marker.

  2002cites this paper
• Circulating Dna: a New Diagnostic Gold Mine? Q

  year unknowncites this paper